Seven Eight Capital’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Seven Eight Capital’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-8,893	Closed	-$284K	–	669
2022 Q2	$284K	Buy	+8,893	New	+$260K	0.11%	267
2021 Q4	–	Sell	-33,338	Closed	-$849K	–	731
2021 Q3	$849K	Buy	+33,338	New	+$980K	0.08%	340
2021 Q2	–	Sell	-28,904	Closed	-$1.25M	–	749
2021 Q1	$1.25M	Hold	28,904	–	–	0.29%	126
2020 Q4	$1.25M	Sell	28,904 -6,539	-18%	-$322K	0.28%	127
2020 Q3	$1.95M	Buy	35,443 +31,243	+744%	+$1.99M	0.42%	35
2020 Q2	$265K	Buy	+4,200	New	+$288K	0.19%	215

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Seven Eight Capital's GBT Position: Q3 2022 in Review

Seven Eight Capital sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 8,893 shares — an estimated $284K sold.

Seven Eight Capital first reported a position in GBT in Q2 2020 and held it in 6 quarters. The position peaked at $1.95M in Q3 2020. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

Seven Eight Capital reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
Seven Eight Capital sold 8,893 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $284K.
Seven Eight Capital first reported a position in Global Blood Therapeutics, Inc. in Q2 2020 and held it in 6 quarters.
Seven Eight Capital's Global Blood Therapeutics, Inc. position peaked at $1.95M in Q3 2020.
247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Seven Eight Capital's 13F filing for Q3 2022, filed 10 Nov 2022.